Pancreatic adenocarcinoma, version 2.2012

Featured updates to the NCCN guidelines

Margaret A. Tempero, J. Pablo Arnoletti, Stephen W. Behrman, Edgar Ben-Josef, Al B. Benson, Ephraim S. Casper, Steven J. Cohen, Brian Czito, Joshua D I Ellenhorn, William G. Hawkins, Joseph Herman, John P. Hoffman, Andrew Ko, Srinadh Komanduri, Albert Koong, Wen Wee Ma, Mokenge P. Malafa, Nipun B. Merchant, Sean J. Mulvihill, Peter Muscarella & 11 others Eric K. Nakakura, Jorge Obando, Martha B. Pitman, Aaron R. Sasson, Anitra Tally, Sarah P. Thayer, Samuel Whiting, Robert A. Wolff, Brian M. Wolpin, Deborah A. Freedman-Cass, Dorothy A. Shead

Research output: Contribution to journalReview article

198 Citations (Scopus)

Abstract

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Pancreatic Adenocarcinoma discuss the workup and management of tumors of the exocrine pancreas. These NCCN Guidelines Insights provide a summary and explanation of major changes to the 2012 NCCN Guidelines for Pancreatic Adenocarcinoma. The panel made 3 significant updates to the guidelines: 1) more detail was added regarding multiphase CT techniques for diagnosis and staging of pancreatic cancer, and pancreas protocol MRI was added as an emerging alternative to CT; 2) the use of a fluoropyrimidine plus oxaliplatin (e.g., 5-FU/leucovorin/oxaliplatin or capecitabine/oxaliplatin) was added as an acceptable chemotherapy combination for patients with advanced or metastatic disease and good performance status as a category 2B recommendation; and 3) the panel developed new recommendations concerning surgical technique and pathologic analysis and reporting.

Original languageEnglish (US)
Pages (from-to)703-713
Number of pages11
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume10
Issue number6
StatePublished - Jun 1 2012
Externally publishedYes

Fingerprint

oxaliplatin
Adenocarcinoma
Guidelines
Pancreatic Neoplasms
Exocrine Pancreas
Leucovorin
Combination Drug Therapy
Practice Guidelines
Fluorouracil
Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

Tempero, M. A., Arnoletti, J. P., Behrman, S. W., Ben-Josef, E., Benson, A. B., Casper, E. S., ... Shead, D. A. (2012). Pancreatic adenocarcinoma, version 2.2012: Featured updates to the NCCN guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 10(6), 703-713.

Pancreatic adenocarcinoma, version 2.2012 : Featured updates to the NCCN guidelines. / Tempero, Margaret A.; Arnoletti, J. Pablo; Behrman, Stephen W.; Ben-Josef, Edgar; Benson, Al B.; Casper, Ephraim S.; Cohen, Steven J.; Czito, Brian; Ellenhorn, Joshua D I; Hawkins, William G.; Herman, Joseph; Hoffman, John P.; Ko, Andrew; Komanduri, Srinadh; Koong, Albert; Ma, Wen Wee; Malafa, Mokenge P.; Merchant, Nipun B.; Mulvihill, Sean J.; Muscarella, Peter; Nakakura, Eric K.; Obando, Jorge; Pitman, Martha B.; Sasson, Aaron R.; Tally, Anitra; Thayer, Sarah P.; Whiting, Samuel; Wolff, Robert A.; Wolpin, Brian M.; Freedman-Cass, Deborah A.; Shead, Dorothy A.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 10, No. 6, 01.06.2012, p. 703-713.

Research output: Contribution to journalReview article

Tempero, MA, Arnoletti, JP, Behrman, SW, Ben-Josef, E, Benson, AB, Casper, ES, Cohen, SJ, Czito, B, Ellenhorn, JDI, Hawkins, WG, Herman, J, Hoffman, JP, Ko, A, Komanduri, S, Koong, A, Ma, WW, Malafa, MP, Merchant, NB, Mulvihill, SJ, Muscarella, P, Nakakura, EK, Obando, J, Pitman, MB, Sasson, AR, Tally, A, Thayer, SP, Whiting, S, Wolff, RA, Wolpin, BM, Freedman-Cass, DA & Shead, DA 2012, 'Pancreatic adenocarcinoma, version 2.2012: Featured updates to the NCCN guidelines', JNCCN Journal of the National Comprehensive Cancer Network, vol. 10, no. 6, pp. 703-713.
Tempero MA, Arnoletti JP, Behrman SW, Ben-Josef E, Benson AB, Casper ES et al. Pancreatic adenocarcinoma, version 2.2012: Featured updates to the NCCN guidelines. JNCCN Journal of the National Comprehensive Cancer Network. 2012 Jun 1;10(6):703-713.
Tempero, Margaret A. ; Arnoletti, J. Pablo ; Behrman, Stephen W. ; Ben-Josef, Edgar ; Benson, Al B. ; Casper, Ephraim S. ; Cohen, Steven J. ; Czito, Brian ; Ellenhorn, Joshua D I ; Hawkins, William G. ; Herman, Joseph ; Hoffman, John P. ; Ko, Andrew ; Komanduri, Srinadh ; Koong, Albert ; Ma, Wen Wee ; Malafa, Mokenge P. ; Merchant, Nipun B. ; Mulvihill, Sean J. ; Muscarella, Peter ; Nakakura, Eric K. ; Obando, Jorge ; Pitman, Martha B. ; Sasson, Aaron R. ; Tally, Anitra ; Thayer, Sarah P. ; Whiting, Samuel ; Wolff, Robert A. ; Wolpin, Brian M. ; Freedman-Cass, Deborah A. ; Shead, Dorothy A. / Pancreatic adenocarcinoma, version 2.2012 : Featured updates to the NCCN guidelines. In: JNCCN Journal of the National Comprehensive Cancer Network. 2012 ; Vol. 10, No. 6. pp. 703-713.
@article{d7b2a616b35c421ba05be21153aadcc0,
title = "Pancreatic adenocarcinoma, version 2.2012: Featured updates to the NCCN guidelines",
abstract = "The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Pancreatic Adenocarcinoma discuss the workup and management of tumors of the exocrine pancreas. These NCCN Guidelines Insights provide a summary and explanation of major changes to the 2012 NCCN Guidelines for Pancreatic Adenocarcinoma. The panel made 3 significant updates to the guidelines: 1) more detail was added regarding multiphase CT techniques for diagnosis and staging of pancreatic cancer, and pancreas protocol MRI was added as an emerging alternative to CT; 2) the use of a fluoropyrimidine plus oxaliplatin (e.g., 5-FU/leucovorin/oxaliplatin or capecitabine/oxaliplatin) was added as an acceptable chemotherapy combination for patients with advanced or metastatic disease and good performance status as a category 2B recommendation; and 3) the panel developed new recommendations concerning surgical technique and pathologic analysis and reporting.",
author = "Tempero, {Margaret A.} and Arnoletti, {J. Pablo} and Behrman, {Stephen W.} and Edgar Ben-Josef and Benson, {Al B.} and Casper, {Ephraim S.} and Cohen, {Steven J.} and Brian Czito and Ellenhorn, {Joshua D I} and Hawkins, {William G.} and Joseph Herman and Hoffman, {John P.} and Andrew Ko and Srinadh Komanduri and Albert Koong and Ma, {Wen Wee} and Malafa, {Mokenge P.} and Merchant, {Nipun B.} and Mulvihill, {Sean J.} and Peter Muscarella and Nakakura, {Eric K.} and Jorge Obando and Pitman, {Martha B.} and Sasson, {Aaron R.} and Anitra Tally and Thayer, {Sarah P.} and Samuel Whiting and Wolff, {Robert A.} and Wolpin, {Brian M.} and Freedman-Cass, {Deborah A.} and Shead, {Dorothy A.}",
year = "2012",
month = "6",
day = "1",
language = "English (US)",
volume = "10",
pages = "703--713",
journal = "Journal of the National Comprehensive Cancer Network : JNCCN",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "6",

}

TY - JOUR

T1 - Pancreatic adenocarcinoma, version 2.2012

T2 - Featured updates to the NCCN guidelines

AU - Tempero, Margaret A.

AU - Arnoletti, J. Pablo

AU - Behrman, Stephen W.

AU - Ben-Josef, Edgar

AU - Benson, Al B.

AU - Casper, Ephraim S.

AU - Cohen, Steven J.

AU - Czito, Brian

AU - Ellenhorn, Joshua D I

AU - Hawkins, William G.

AU - Herman, Joseph

AU - Hoffman, John P.

AU - Ko, Andrew

AU - Komanduri, Srinadh

AU - Koong, Albert

AU - Ma, Wen Wee

AU - Malafa, Mokenge P.

AU - Merchant, Nipun B.

AU - Mulvihill, Sean J.

AU - Muscarella, Peter

AU - Nakakura, Eric K.

AU - Obando, Jorge

AU - Pitman, Martha B.

AU - Sasson, Aaron R.

AU - Tally, Anitra

AU - Thayer, Sarah P.

AU - Whiting, Samuel

AU - Wolff, Robert A.

AU - Wolpin, Brian M.

AU - Freedman-Cass, Deborah A.

AU - Shead, Dorothy A.

PY - 2012/6/1

Y1 - 2012/6/1

N2 - The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Pancreatic Adenocarcinoma discuss the workup and management of tumors of the exocrine pancreas. These NCCN Guidelines Insights provide a summary and explanation of major changes to the 2012 NCCN Guidelines for Pancreatic Adenocarcinoma. The panel made 3 significant updates to the guidelines: 1) more detail was added regarding multiphase CT techniques for diagnosis and staging of pancreatic cancer, and pancreas protocol MRI was added as an emerging alternative to CT; 2) the use of a fluoropyrimidine plus oxaliplatin (e.g., 5-FU/leucovorin/oxaliplatin or capecitabine/oxaliplatin) was added as an acceptable chemotherapy combination for patients with advanced or metastatic disease and good performance status as a category 2B recommendation; and 3) the panel developed new recommendations concerning surgical technique and pathologic analysis and reporting.

AB - The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Pancreatic Adenocarcinoma discuss the workup and management of tumors of the exocrine pancreas. These NCCN Guidelines Insights provide a summary and explanation of major changes to the 2012 NCCN Guidelines for Pancreatic Adenocarcinoma. The panel made 3 significant updates to the guidelines: 1) more detail was added regarding multiphase CT techniques for diagnosis and staging of pancreatic cancer, and pancreas protocol MRI was added as an emerging alternative to CT; 2) the use of a fluoropyrimidine plus oxaliplatin (e.g., 5-FU/leucovorin/oxaliplatin or capecitabine/oxaliplatin) was added as an acceptable chemotherapy combination for patients with advanced or metastatic disease and good performance status as a category 2B recommendation; and 3) the panel developed new recommendations concerning surgical technique and pathologic analysis and reporting.

UR - http://www.scopus.com/inward/record.url?scp=84863206071&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863206071&partnerID=8YFLogxK

M3 - Review article

VL - 10

SP - 703

EP - 713

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

SN - 1540-1405

IS - 6

ER -